Your browser is no longer supported. Please, upgrade your browser.
Settings
IMMY Imprimis Pharmaceuticals, Inc. daily Stock Chart
IMMY [NASD]
Imprimis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.31 Insider Own3.90% Shs Outstand22.67M Perf Week28.90%
Market Cap138.51M Forward P/E- EPS next Y- Insider Trans-16.13% Shs Float21.60M Perf Month40.78%
Income-6.30M PEG- EPS next Q- Inst Own23.30% Short Float0.51% Perf Quarter105.72%
Sales37.30M P/S3.71 EPS this Y60.00% Inst Trans69.73% Short Ratio0.32 Perf Half Y152.48%
Book/sh0.21 P/B29.10 EPS next Y- ROA-25.20% Target Price5.00 Perf Year253.18%
Cash/sh0.28 P/C21.99 EPS next 5Y15.00% ROE-230.70% 52W Range1.45 - 6.50 Perf YTD259.41%
Dividend- P/FCF- EPS past 5Y13.60% ROI-35.70% 52W High-6.00% Beta-0.87
Dividend %- Quick Ratio0.90 Sales past 5Y205.90% Gross Margin57.50% 52W Low321.09% ATR0.48
Employees128 Current Ratio1.10 Sales Q/Q64.60% Oper. Margin0.20% RSI (14)75.69 Volatility11.78% 10.61%
OptionableYes Debt/Eq3.40 EPS Q/Q58.80% Profit Margin-16.80% Rel Volume2.24 Prev Close5.95
ShortableYes LT Debt/Eq2.82 EarningsNov 20 AMC Payout- Avg Volume342.15K Price6.11
Recom2.00 SMA2027.16% SMA5051.57% SMA200118.89% Volume765,957 Change2.69%
Dec-10-18Initiated Lake Street Buy $10
Nov-28-16Initiated Rodman & Renshaw Buy $5
Jul-23-15Initiated Sterne Agee CRT Buy
Dec-18-14Initiated CRT Capital Buy $13
Nov-27-18 08:00AM  Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-19-18 09:00AM  4 Healthcare Stocks Taking a New Approach to Growth Trends ACCESSWIRE -5.48%
Nov-16-18 07:30AM  Imprimis Pharmaceuticals Ranked 88th Fastest Growing Company in North America on Deloittes 2018 Technology Fast 500 GlobeNewswire +12.31%
Nov-14-18 10:25AM  4 Healthcare Stocks Investors Should Get Familiar With ACCESSWIRE +19.43%
Nov-13-18 04:15PM  Imprimis: 3Q Earnings Snapshot Associated Press -10.23%
04:01PM  Imprimis Pharmaceuticals Announces Third Quarter 2018 Results GlobeNewswire
Nov-06-18 07:00AM  Imprimis Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 13, 2018 GlobeNewswire
Oct-23-18 07:00AM  Imprimis Pharmaceuticals Subsidiary Melt Pharmaceuticals Initiates Clinical Development Program for its Patented Non-Opioid and Non-Invasive MK Melt Conscious Sedation Drug Candidate GlobeNewswire
Oct-16-18 08:10AM  Analysis: Positioning to Benefit within Kopin, MDC Partners, Dova Pharmaceuticals, Revlon, Imprimis Pharmaceuticals, and Minerva Neurosciences Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +5.45%
07:00AM  ImprimisRx to feature new formulation and poster presentation on MKO Melt® at the upcoming American Academy of Ophthalmology Meeting in Chicago GlobeNewswire
Oct-12-18 03:17PM  10 Small-Caps With Straight-A Potential InvestorPlace +31.11%
Aug-15-18 07:50AM  Consolidated Research: 2018 Summary Expectations for FTD Companies, PRA Group, Equity Bancshares, ConforMIS, Immune Design, and Imprimis Pharmaceuticals Fundamental Analysis, Key Performance Indications GlobeNewswire
Aug-06-18 04:29PM  Imprimis: 2Q Earnings Snapshot Associated Press
04:01PM  Imprimis Pharmaceuticals Announces Second Quarter 2018 Results PR Newswire
02:30PM  Imprimis Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 07:30AM  Imprimis Announces Multi-Center Clinical Trial for Dropless® TriMoxi (Triamcinolone Acetonide-Moxifloxacin for injection) Formulation in Canada PR Newswire
Jul-31-18 07:30AM  Imprimis Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 6, 2018 GlobeNewswire
Jul-18-18 07:30AM  Imprimis Pharmaceuticals to Present at the Canaccord Genuity 38th Annual Growth Conference on August 9, 2018 PR Newswire
May-30-18 07:30AM  ImprimisRx's Dropless® Steroid and Antibiotic Intravitreal Injection Featured in the Prestigious Journal of Cataract and Refractive Surgery PR Newswire
May-29-18 07:40AM  Blog Exposure - Emergent BioSolutions and Profectus BioSciences Receive Contract from CEPI to Develop Nipah Virus Vaccine ACCESSWIRE
May-15-18 07:22PM  Imprimis: 1Q Earnings Snapshot Associated Press +6.22%
04:01PM  Imprimis Pharmaceuticals Announces First Quarter 2018 Results PR Newswire
07:30AM  Surface Pharmaceuticals, Inc. Announces $20 Million Series A Financing from Flying L Partners PR Newswire
May-02-18 07:30AM  Imprimis Pharmaceuticals to Host its First Quarter 2018 Financial Report Conference Call and Webcast on May 15, 2018 at 4:30 p.m. EDT GlobeNewswire
May-01-18 03:30PM  Imprimis Pharmaceuticals Inc (NASDAQ:IMMY): Time For A Financial Health Check Simply Wall St.
Apr-30-18 08:00AM  Research Report Identifies Albany International, JBG SMITH Properties, Preferred Apartment Communities, National Western Life Group, Phibro Animal Health, and Imprimis Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Apr-20-18 01:54PM  Does Imprimis Pharmaceuticals Incs (NASDAQ:IMMY) CEO Salary Compare Well With Others? Simply Wall St.
Apr-10-18 07:30AM  Imprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt® (midazolam/ketamine/ondansetron) formulations at the upcoming Cataract & Refractive Surgery Medical Meeting PR Newswire +8.04%
Mar-27-18 07:30AM  Imprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation Formulation PR Newswire
Mar-19-18 07:35AM  Analysis: Positioning to Benefit within Enbridge Energy Management, Imprimis Pharmaceuticals, Hibbett Sports, Glacier, Regis, and Fox Factory Holding Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-08-18 05:14PM  Imprimis reports 4Q loss Associated Press
04:01PM  Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results PR Newswire
12:15PM  Imprimis Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
07:50AM  Wired News Imprimis Pharma Launched New Program for Custom Compounded Ophthalmic Medications ACCESSWIRE
Mar-07-18 07:30AM  Imprimis Pharmaceuticals to Present at 30th Annual ROTH Conference on March 13, 2018 PR Newswire
Mar-06-18 07:30AM  Imprimis Pharmaceuticals Announces Program for Custom Compounded Ophthalmic Formulations PR Newswire
Feb-28-18 02:19PM  Should You Be Content With Imprimis Pharmaceuticals Incs (NASDAQ:IMMY) Earnings Growth? Simply Wall St.
Feb-15-18 07:30AM  Imprimis Pharmaceuticals to Host its Fourth Quarter 2017 Financial Report Conference Call and Webcast on March 8, 2018 at 4:30 p.m. EST PR Newswire +5.52%
Jan-31-18 08:10AM  Todays Research Reports on Trending Tickers: Corbus Pharmaceuticals and Imprimis Pharmaceuticals ACCESSWIRE
Jan-30-18 07:21PM  Who Owns Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)? Simply Wall St. +14.29%
07:30AM  Imprimis Pharmaceuticals Now Making Available Two Glaucoma Drugs on FDA's Drug Shortage List PR Newswire
Jan-26-18 07:00AM  Blog Exposure - Imprimis Pharma Received DEA Manufacturer Certificate for 503B Outsourcing Facility ACCESSWIRE +7.64%
Jan-24-18 07:30AM  Imprimis Pharmaceuticals is Issued DEA Manufacturer Certificate for its 503B Outsourcing Facility PR Newswire
Jan-22-18 01:10PM  What You Must Know About Imprimis Pharmaceuticals Incs (NASDAQ:IMMY) Financial Strength Simply Wall St.
Jan-17-18 08:05AM  Report: Exploring Fundamental Drivers Behind Hibbett Sports, Fox Factory Holding, Triangle Capital, Silgan, Imprimis Pharmaceuticals, and On Deck Capital New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jan-16-18 04:59PM  Imprimis receives FDA warning over eye medication advertising Reuters -12.43%
Jan-15-18 09:11AM  NasdaqCM Healthcare Industry: A Deep Dive Into Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) Simply Wall St.
Jan-04-18 12:50PM  Is Imprimis Pharmaceuticals Incs (NASDAQ:IMMY) CEO Pay Justified? Simply Wall St.
Dec-26-17 11:39AM  ETFs with exposure to Imprimis Pharmaceuticals, Inc. : December 26, 2017 Capital Cube
Dec-25-17 09:21AM  Imprimis Pharmaceuticals, Inc. :IMMY-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 Capital Cube
Nov-29-17 11:17AM  Imprimis Pharmaceuticals Inc (IMMY): Has Recent Earnings Growth Beaten Long-Term Trend? Simply Wall St.
Nov-16-17 05:14AM  Imprimis reports 3Q loss Associated Press
Nov-14-17 04:01PM  Imprimis Pharmaceuticals Announces Third Quarter 2017 Results PR Newswire
Nov-13-17 04:30PM  Investor Network Invites You to the Imprimis Pharmaceuticals Third Quarter 2017 Earnings Conference Call and Webcast Live on Tuesday, November 14, 2017 ACCESSWIRE
Nov-10-17 12:37PM  ETFs with exposure to Imprimis Pharmaceuticals, Inc. : November 10, 2017 Capital Cube
Oct-31-17 07:30AM  Imprimis Pharmaceuticals to Host its Third Quarter 2017 Financial Report Conference Call and Webcast on November 14, 2017 at 4:15 p.m. EST PR Newswire
Oct-24-17 07:30AM  Imprimis Launches Surface Pharmaceuticals Subsidiary PR Newswire
Oct-20-17 11:36AM  What does Imprimis Pharmaceuticals Incs (IMMY) Balance Sheet Tell Us Abouts Its Future? Simply Wall St.
08:10AM  Today's Research Reports on Stocks to Watch: Alcobra and Imprimis Pharmaceuticals ACCESSWIRE
Oct-19-17 11:29PM  Imprimis Pharma to take on Allergan's Restasis with cheaper product Reuters +28.77%
10:49AM  Imprimis Pharmaceuticals Inc (IMMY) Stock: Gaining On Generic Version of Restasis SmarterAnalyst
07:30AM  Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis® PR Newswire
Oct-17-17 09:46AM  ETFs with exposure to Imprimis Pharmaceuticals, Inc. : October 17, 2017 Capital Cube
Oct-06-17 10:54AM  ETFs with exposure to Imprimis Pharmaceuticals, Inc. : October 6, 2017 Capital Cube
Oct-05-17 10:06AM  Whats The Outlook For Loss-Making Imprimis Pharmaceuticals Inc (IMMY)? Simply Wall St.
Oct-02-17 07:30AM  Imprimis Pharmaceuticals Secures First Key Composition Patent for Dropless Therapy® Formulations PR Newswire +8.70%
Sep-22-17 11:13AM  ETFs with exposure to Imprimis Pharmaceuticals, Inc. : September 22, 2017 Capital Cube
Sep-20-17 12:43PM  Imprimis Pharmaceuticals, Inc. :IMMY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017 Capital Cube
Sep-14-17 08:00AM  FDA Curcumin Investigation Supports Imprimis Statement PR Newswire +6.47%
Sep-11-17 07:30AM  Imprimis Releases Statement Regarding Allergan Lawsuit PR Newswire
Aug-10-17 10:11PM  Imprimis posts 2Q profit Associated Press -7.05%
04:01PM  Imprimis Pharmaceuticals Announces Second Quarter 2017 Financial Results PR Newswire
12:00PM  Investor Network: Imprimis Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-09-17 04:15PM  Investor Network Invites You to the Imprimis Pharmaceuticals Second Quarter 2017 Earnings Conference Call and Webcast Live on Thursday, August 10, 2017 ACCESSWIRE
Aug-07-17 08:00AM  Imprimis Statement Regarding Curcumin Emulsion FDA MedWatch Notice PR Newswire
Aug-05-17 12:42PM  FDA Links Naturopathic Turmeric Death To Contaminated Product Forbes
Jul-31-17 08:00AM  Imprimis Pharmaceuticals to Host its Second Quarter 2017 Financial Report Conference Call and Webcast on August 10, 2017 at 4:15 p.m. EDT PR Newswire
Jul-27-17 08:00AM  Imprimis Pharmaceuticals Patent-Pending Dropless and LessDrops Formulations Exceed One Million Patient Eyes Milestone PR Newswire
Jul-20-17 08:00AM  Imprimis Pharmaceuticals Announces $16 Million Debt Facility with SWK Holdings PR Newswire
Jun-29-17 08:00AM  Imprimis Pharmaceuticals Sells Pennsylvania Facility and Sinus Assets PR Newswire
Jun-23-17 08:00AM  Eton Pharmaceuticals Names Sean Brynjelsen Chief Executive Officer and Director PR Newswire
Jun-20-17 04:01PM  Eton Pharmaceuticals Announces $20 Million Series A Financing PR Newswire +6.05%
Jun-19-17 03:31PM  ETFs with exposure to Imprimis Pharmaceuticals, Inc. : June 19, 2017 Capital Cube
Jun-08-17 01:40PM  ETFs with exposure to Imprimis Pharmaceuticals, Inc. : June 8, 2017 Capital Cube
Jun-06-17 09:24AM  Imprimis Pharmaceuticals, Inc. :IMMY-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6, 2017 Capital Cube -5.66%
Jun-02-17 08:30AM  Imprimis Pharmaceuticals (IMMY) Looks Good: Stock Up 13% Zacks +10.48%
May-10-17 04:22PM  Imprimis reports 1Q loss Associated Press
04:01PM  Imprimis Pharmaceuticals Announces First Quarter 2017 Financial Results PR Newswire
09:45AM  Investor Network: Imprimis Pharmaceuticals, Inc. to Host Earnings Call Accesswire
May-09-17 04:15PM  Investor Network Invites You to the Imprimis Pharmaceuticals First Quarter 2017 Earnings Conference Call and Webcast Live on Wednesday, May 10, 2017 Accesswire
May-04-17 08:30AM  Imprimis Pharmaceuticals to Launch its Simple Drops Combination Glaucoma Drops at Leading Cataract & Refractive Surgery Medical Meeting PR Newswire
May-02-17 08:30AM  Imprimis Pharmaceuticals and SightLife Surgical Sign Agreement for National Launch of Serum Tears PR Newswire
May-01-17 08:30AM  Imprimis Pharmaceuticals to Host its First Quarter 2017 Financial Report Conference Call and Webcast on May 10, 2017 at 4:15 p.m. EDT PR Newswire
Apr-21-17 05:24AM  Can The Uptrend Continue for Imprimis Pharmaceuticals (IMMY)? Zacks
Apr-18-17 08:30AM  Imprimis Pharmaceuticals and Precision Lens Sign Agreement to Expand Imprimis' Ophthalmic Portfolio Market Opportunity in the U.S. Midwest PR Newswire
Apr-07-17 04:52PM  ETFs with exposure to Imprimis Pharmaceuticals, Inc. : April 7, 2017 Capital Cube
Apr-06-17 08:30AM  Imprimis Pharmaceuticals Acquires Exclusive License to Patented Ophthalmic Formulation for Dry Eye Disease PR Newswire
Mar-31-17 12:55PM  Can The Uptrend Continue for Teck Resources (IMMY)? Zacks
Mar-30-17 11:15AM  Top Ranked Momentum Stocks to Buy for March 30th Zacks +5.76%
Mar-27-17 03:59PM  ETFs with exposure to Imprimis Pharmaceuticals, Inc. : March 27, 2017 Capital Cube +11.35%
Imprimis Pharmaceuticals, Inc., an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications. The company also develops and commercializes therapeutics for the ocular surface diseases. In addition, it provides patent-pending preservative-free topical eye drop drug candidates, including SURF-100, an immunosuppressive drug that inhibits t-cell proliferation and replication in the dry eye disease (DED); SURF-200 for the patients with episodic DED; and SURF-300, a combination of a low-dose of doxycycline and a proprietary powderized triglyceride Omega-3 for the refractory DED patients with chronic DED symptoms. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kammer Robert JDirectorDec 03Sale4.6410,00046,400889,827Dec 06 06:09 AM
Kammer Robert JDirectorNov 01Sale4.2110,00042,100899,827Nov 02 06:20 PM
Kammer Robert JDirectorOct 15Sale3.0010,00030,000909,827Oct 18 09:10 AM
Kammer Robert JDirectorSep 04Sale3.0010,00030,000919,827Sep 05 07:45 PM
Kammer Robert JDirectorAug 10Sale3.00130,000390,000929,827Aug 15 06:05 AM
SAHAREK JOHN P.Chief Commercial OfficerFeb 01Option Exercise1.8330,00054,90030,000Feb 02 09:00 PM
BOLL ANDREW R.Chief Financial OfficerFeb 01Option Exercise1.8330,00054,90084,000Feb 02 08:58 PM